171 related articles for article (PubMed ID: 36923280)
1. Impaired Antitumor Immune Response in
Kacher J; Manches O; Aspord C; Sartelet H; Chaperot L
Cancer Res Commun; 2022 Jul; 2(7):577-589. PubMed ID: 36923280
[TBL] [Abstract][Full Text] [Related]
2. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.
Song L; Ara T; Wu HW; Woo CW; Reynolds CP; Seeger RC; DeClerck YA; Thiele CJ; Sposto R; Metelitsa LS
J Clin Invest; 2007 Sep; 117(9):2702-12. PubMed ID: 17710228
[TBL] [Abstract][Full Text] [Related]
3. Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk
Wei JS; Kuznetsov IB; Zhang S; Song YK; Asgharzadeh S; Sindiri S; Wen X; Patidar R; Najaraj S; Walton A; Auvil JMG; Gerhard DS; Yuksel A; Catchpoole D; Hewitt SM; Sondel PM; Seeger R; Maris JM; Khan J
Clin Cancer Res; 2018 Nov; 24(22):5673-5684. PubMed ID: 29784674
[No Abstract] [Full Text] [Related]
4. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2.
Metelitsa LS; Wu HW; Wang H; Yang Y; Warsi Z; Asgharzadeh S; Groshen S; Wilson SB; Seeger RC
J Exp Med; 2004 May; 199(9):1213-21. PubMed ID: 15123743
[TBL] [Abstract][Full Text] [Related]
5. Thymidylate synthase inhibitor raltitrexed can induce high levels of DNA damage in MYCN-amplified neuroblastoma cells.
Yamashita K; Kiyonari S; Tsubota S; Kishida S; Sakai R; Kadomatsu K
Cancer Sci; 2020 Jul; 111(7):2431-2439. PubMed ID: 32415892
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of MYCN amplification in patients with high-risk neuroblastoma.
Lee JW; Son MH; Cho HW; Ma YE; Yoo KH; Sung KW; Koo HH
Pediatr Blood Cancer; 2018 Oct; 65(10):e27257. PubMed ID: 29797634
[TBL] [Abstract][Full Text] [Related]
7. Direct Targeting of
Yoda H; Inoue T; Shinozaki Y; Lin J; Watanabe T; Koshikawa N; Takatori A; Nagase H
Cancer Res; 2019 Feb; 79(4):830-840. PubMed ID: 30584073
[TBL] [Abstract][Full Text] [Related]
8. MYCN Amplified Relapse Following Resolution of MYCN Nonamplified 4S Neuroblastoma With Placental Involvement: A Case Report and Review of the Literature.
Langenberg-Ververgaert KPS; Renzi S; Chung CT; Shago M; Lo W; Davidson S; Villani A; Baruchel S; Irwin MS; Morgenstern DA
J Pediatr Hematol Oncol; 2019 Jul; 41(5):388-391. PubMed ID: 31094905
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma.
Hungate EA; Applebaum MA; Skol AD; Vaksman Z; Diamond M; McDaniel L; Volchenboum SL; Stranger BE; Maris JM; Diskin SJ; Onel K; Cohn SL
J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 29117357
[TBL] [Abstract][Full Text] [Related]
10. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
[TBL] [Abstract][Full Text] [Related]
11. Identification of hub genes and their correlation with infiltration of immune cells in
Chen J; Sun M; Chen C; Jiang B; Fang Y
Front Immunol; 2022; 13():1016683. PubMed ID: 36311753
[TBL] [Abstract][Full Text] [Related]
12. FOXR2 Stabilizes MYCN Protein and Identifies Non-
Schmitt-Hoffner F; van Rijn S; Toprak UH; Mauermann M; Rosemann F; Heit-Mondrzyk A; Hübner JM; Camgöz A; Hartlieb S; Pfister SM; Henrich KO; Westermann F; Kool M
J Clin Oncol; 2021 Oct; 39(29):3217-3228. PubMed ID: 34110923
[TBL] [Abstract][Full Text] [Related]
13. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
Aygun N; Altungoz O
Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
[TBL] [Abstract][Full Text] [Related]
14. Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence.
Taschner-Mandl S; Schwarz M; Blaha J; Kauer M; Kromp F; Frank N; Rifatbegovic F; Weiss T; Ladenstein R; Hohenegger M; Ambros IM; Ambros PF
Oncotarget; 2016 Jan; 7(3):3571-86. PubMed ID: 26657295
[TBL] [Abstract][Full Text] [Related]
15. p53 is a direct transcriptional target of MYCN in neuroblastoma.
Chen L; Iraci N; Gherardi S; Gamble LD; Wood KM; Perini G; Lunec J; Tweddle DA
Cancer Res; 2010 Feb; 70(4):1377-88. PubMed ID: 20145147
[TBL] [Abstract][Full Text] [Related]
16. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
[TBL] [Abstract][Full Text] [Related]
17. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
[TBL] [Abstract][Full Text] [Related]
18. Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[
Li C; Huang S; Guo J; Wang C; Huang Z; Huang R; Liu L; Liang S; Wang H
Mol Imaging Biol; 2019 Dec; 21(6):1117-1126. PubMed ID: 30850970
[TBL] [Abstract][Full Text] [Related]
19. Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma.
Lucarini V; Melaiu O; D'Amico S; Pastorino F; Tempora P; Scarsella M; Pezzullo M; De Ninno A; D'Oria V; Cilli M; Emionite L; Infante P; Di Marcotullio L; De Ioris MA; Barillari G; Alaggio R; Businaro L; Ponzoni M; Locatelli F; Fruci D
J Exp Clin Cancer Res; 2022 Nov; 41(1):326. PubMed ID: 36397148
[TBL] [Abstract][Full Text] [Related]
20. 2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics.
Jeison M; Ash S; Halevy-Berko G; Mardoukh J; Luria D; Avigad S; Feinberg-Gorenshtein G; Goshen Y; Hertzel G; Kapelushnik J; Ben Barak A; Attias D; Steinberg R; Stein J; Stark B; Yaniv I
Am J Pathol; 2010 Jun; 176(6):2616-25. PubMed ID: 20395439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
